TP53 and cancer: Beyond tumor IDO1 expression, assessment of other factors such as IDO enzymatic activity, the status of the p53 pathway in the cancer cells, and the availability of free fatty acids in the tumor microenvironment, i.e., the application of a more personalized medicine, may help IDO1 inhibitors to find their place in cancer immunotherapy.